menu

CME: The Winding Road to Biosimilar Adoption in the United States

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

The Winding Road to Biosimilar Adoption in the United States

Program Information
Recommended
The Winding Road to Biosimilar Adoption in the United States
RestartResume
If you’re uncertain about the safety of biosimilars, you’re not alone. But combating common misconceptions is key to adopting them into practice.

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Biosimilars are expected to provide patients access to promising and often lifesaving medications while lowering overall healthcare system costs. Nonetheless, there remains complex barriers to achieving this goal in the United States. Join us as we delve into and seek answers to these critical issues.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host: 
    Jennifer Caudle, DO
    Family Medicine Physician and Assistant Professor
    Department of Family Medicine
    Rowan University-School of Osteopathic Medicine
    Stratford, New Jersey

    Dr. Caudle has no financial relationships to disclose. 

    Faculty: 
    Cate Lockhart, PharmD, PhD
    Executive Director
    Biologics and Biosimilars Collective Intelligence Consortium (BBCIC)
    Alexandria, VA

    Dr. Lockhart has no financial relationships to disclose.  

    Reviewers/Content Planners/Authors:

    • Ken Brown has nothing to disclose.
    • Barry A. Fiedel, PhD has nothing to disclose.
    • Jessica McGrory has nothing to disclose.
    • Ashley Rosenthal has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Explain how biosimilars are different from generic drugs and how their use can provide a more cost-effective delivery of healthcare for both health systems and patients.
    • Describe the key misconceptions concerning biosimilars, their impact on biosimilar uptake, and the barriers to adoption faced by the relevant vested parties.
    • Compare and contrast the European experience with biosimilars to the current environment in the United States (U.S.); and how partnerships could hasten biosimilar adoption in the US.
  • Target Audience

    This activity is designed to meet the educational needs of  managed care and IDS medical directors, executive policy-makers,  rheumatologists, dermatologists, gastroenterologists, hematologists, and oncologists.

  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.

  • Commercial Support

    This activity is supported by an independent educational grant from Merck.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of TOPEC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 8/20/19

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.